Matthew J. Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew J. Chung has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Amit N. Vora
Division of Cardiology, Duke University Medical Center, Durham, North Carolina
1 shared publication- Andrew S. Perry
Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center , Nashville, TN
1 shared publication Asvin M. Ganapathi
Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, North Carolina
1 shared publicationBennet George
Division of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, Kentucky, USA
1 shared publication- David L. Brown
Cardiovascular Division, Washington University School of Medicine, St Louis, Missouri
1 shared publication - Eric Novak
Cardiovascular Division, Washington University School of Medicine, St. Louis, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2020
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 10 (1) , 98-100
Training in structural heart disease: a fellow’s perspective
Training in structural heart disease: a fellow’s perspective
- 1 February 2020
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 10 (1) , 98-100
Open AccessTraining in structural heart disease: a fellow’s perspective
Training in structural heart disease: a fellow’s perspective
- 22 August 2019
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 109 (3) , e163-e165
Valve-in-Ring Transcatheter Aortic Valve Replacement After Left Ventricular Assist Device Therapy
- 22 August 2019
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 109 (3) , e163-e165
Valve-in-Ring Transcatheter Aortic Valve Replacement After Left Ventricular Assist Device Therapy
- Open Access
- 14 February 2019
- Published by Springer Nature in Diagnostic and Prognostic Research
- Vol. 3 (1) , 1-9
Development of a risk score to identify patients with type 2 diabetes mellitus and multivessel coronary artery disease who can defer bypass surgery
Current American College of Cardiology/American Heart Association (ACC/AHA) guidelines provide a class I recommendation for patients with type 2 diabetes mellitus and multivessel coronary artery disease (CAD) to be treated with coronary artery bypass graft surgery (CABG). However, these patients are heterogeneous in terms of the risks and benefits associated with CABG. We sought to develop a risk score to identify low-risk patients with diabetes and multivessel CAD in whom CABG can be safely deferred. Patients in the CABG strata randomized to intensive medical therapy (IMT) in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial who experienced death, myocardial infarction (MI), or stroke were compared with those who did not. We developed a risk score for death, MI, or stroke using a Cox proportional hazards model that included the following variables: age, history of heart failure, history of hypercholesterolemia, history of stroke, transient ischemic attack, serum creatinine, insulin use, myocardial jeopardy index, and HbA1c. Among patients with a risk score less than the median, those randomized to IMT or prompt CABG experienced similar rates of event-free survival at 5 years (77.8% vs. 83.2%, logrank P = 0.24). Among patients with a risk score greater than the median, those randomized to IMT experienced worse rates of event-free survival at 5 years than those randomized to prompt CABG (60.3% vs 73.2%, logrank P = 0.01). A novel risk score identifies low-risk patients with diabetes and stable, symptomatic multivessel CAD in whom CABG can be safely deferred.
- 14 February 2019
- Published by Springer Nature in Diagnostic and Prognostic Research
- Vol. 3 (1) , 1-9
Open AccessDevelopment of a risk score to identify patients with type 2 diabetes mellitus and multivessel coronary artery disease who can defer bypass surgery
Current American College of Cardiology/American Heart Association (ACC/AHA) guidelines provide a class I recommendation for patients with type 2 diabetes mellitus and multivessel coronary artery disease (CAD) to be treated with coronary artery bypass graft surgery (CABG). However, these patients are heterogeneous in terms of the risks and benefits associated with CABG. We sought to develop a risk score to identify low-risk patients with diabetes and multivessel CAD in whom CABG can be safely deferred. Patients in the CABG strata randomized to intensive medical therapy (IMT) in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial who experienced death, myocardial infarction (MI), or stroke were compared with those who did not. We developed a risk score for death, MI, or stroke using a Cox proportional hazards model that included the following variables: age, history of heart failure, history of hypercholesterolemia, history of stroke, transient ischemic attack, serum creatinine, insulin use, myocardial jeopardy index, and HbA1c. Among patients with a risk score less than the median, those randomized to IMT or prompt CABG experienced similar rates of event-free survival at 5 years (77.8% vs. 83.2%, logrank P = 0.24). Among patients with a risk score greater than the median, those randomized to IMT experienced worse rates of event-free survival at 5 years than those randomized to prompt CABG (60.3% vs 73.2%, logrank P = 0.01). A novel risk score identifies low-risk patients with diabetes and stable, symptomatic multivessel CAD in whom CABG can be safely deferred.